ATyr Pharma Analyst Ratings
ATyr Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/21/2023 | 2060.49% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy |
| 09/14/2023 | 2060.49% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy |
| 08/10/2023 | 2060.49% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy |
| 07/21/2023 | 1134.57% | Piper Sandler | $13 → $20 | Maintains | Overweight |
| 07/05/2023 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 05/23/2023 | 2060.49% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy |
| 05/10/2023 | 1072.84% | RBC Capital | → $19 | Reiterates | → Outperform |
| 04/11/2023 | 702.47% | Piper Sandler | $9 → $13 | Maintains | Overweight |
| 03/10/2023 | 1072.84% | RBC Capital | → $19 | Reiterates | → Outperform |
| 03/10/2023 | 2060.49% | HC Wainwright & Co. | → $35 | Reiterates | → Buy |
| 03/06/2023 | 455.56% | Roth MKM | → $9 | Reinstates | → Buy |
| 03/02/2023 | 1072.84% | RBC Capital | $20 → $19 | Maintains | Outperform |
| 02/07/2023 | 2060.49% | HC Wainwright & Co. | → $35 | Reiterates | → Buy |
| 08/16/2022 | 764.2% | Piper Sandler | $11 → $14 | Maintains | Overweight |
| 07/21/2022 | 2060.49% | HC Wainwright & Co. | $11 → $35 | Maintains | Buy |
| 05/18/2022 | 579.01% | Piper Sandler | $19 → $11 | Maintains | Overweight |
| 05/10/2022 | 1134.57% | RBC Capital | $22 → $20 | Maintains | Outperform |
| 11/11/2021 | 579.01% | HC Wainwright & Co. | $18 → $11 | Maintains | Buy |
| 10/12/2021 | 1258.02% | RBC Capital | → $22 | Initiates Coverage On | → Outperform |
| 09/21/2021 | 1072.84% | Piper Sandler | → $19 | Initiates Coverage On | → Overweight |
| 09/14/2021 | 1196.3% | Roth Capital | $20 → $21 | Maintains | Buy |
| 09/14/2021 | 1134.57% | Oppenheimer | $14 → $20 | Maintains | Outperform |
| 09/13/2021 | 1011.11% | HC Wainwright & Co. | $13 → $18 | Maintains | Buy |
| 05/18/2021 | 825.93% | JonesTrading | → $15 | Initiates Coverage On | → Buy |
| 03/24/2021 | 764.2% | Oppenheimer | $12 → $14 | Maintains | Outperform |
| 03/16/2021 | 1134.57% | Roth Capital | $15 → $20 | Maintains | Buy |
| 08/17/2020 | 702.47% | HC Wainwright & Co. | → $13 | Upgrades | Neutral → Buy |
| 03/27/2020 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 03/02/2020 | 393.83% | Oppenheimer | → $8 | Initiates Coverage On | → Outperform |
| 11/05/2019 | 393.83% | HC Wainwright & Co. | → $8 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年09月21日 | 2060.49% | HC Wainwright公司 | →$35 | 重申 | 購買→購買 |
| 09/14/2023 | 2060.49% | HC Wainwright公司 | →$35 | 重申 | 購買→購買 |
| 2023年08月10日 | 2060.49% | HC Wainwright公司 | →$35 | 重申 | 購買→購買 |
| 07/21/2023 | 1134.57% | 派珀·桑德勒 | $13→$20 | 維護 | 超重 |
| 07/05/2023 | - | 奧本海默 | 評級下調 | 超越→表現 | |
| 2023年05月23日 | 2060.49% | HC Wainwright公司 | →$35 | 重申 | 購買→購買 |
| 2023年05月10日 | 1072.84% | 加拿大皇家銀行資本 | →$19 | 重申 | →跑贏大盤 |
| 04/11/2023 | 702.47% | 派珀·桑德勒 | $9→$13 | 維護 | 超重 |
| 03/10/2023 | 1072.84% | 加拿大皇家銀行資本 | →$19 | 重申 | →跑贏大盤 |
| 03/10/2023 | 2060.49% | HC Wainwright公司 | →$35 | 重申 | →購買 |
| 03/06/2023 | 455.56% | 羅斯MKM | →$9 | 恢復 | →購買 |
| 03/02/2023 | 1072.84% | 加拿大皇家銀行資本 | $20→$19 | 維護 | 跑贏大盤 |
| 02/07/2023 | 2060.49% | HC Wainwright公司 | →$35 | 重申 | →購買 |
| 08/16/2022 | 764.2% | 派珀·桑德勒 | $11→$14 | 維護 | 超重 |
| 07/21/2022 | 2060.49% | HC Wainwright公司 | $11→$35 | 維護 | 買 |
| 2022/05/18 | 579.01% | 派珀·桑德勒 | $19→$11 | 維護 | 超重 |
| 2022年05月10日 | 1134.57% | 加拿大皇家銀行資本 | $22→$20 | 維護 | 跑贏大盤 |
| 2021年11月11日 | 579.01% | HC Wainwright公司 | $18→$11 | 維護 | 買 |
| 10/12/2021 | 1258.02% | 加拿大皇家銀行資本 | →$22 | 開始承保 | →跑贏大盤 |
| 2021/09/21 | 1072.84% | 派珀·桑德勒 | →$19 | 開始承保 | →超重 |
| 09/14/2021 | 1196.3% | 羅斯資本 | $20→$21 | 維護 | 買 |
| 09/14/2021 | 1134.57% | 奧本海默 | $14→$20 | 維護 | 跑贏大盤 |
| 09/13/2021 | 1011.11% | HC Wainwright公司 | $13→$18 | 維護 | 買 |
| 2021/05/18 | 825.93% | Jones Trading | →$15 | 開始承保 | →購買 |
| 03/24/2021 | 764.2% | 奧本海默 | $12→$14 | 維護 | 跑贏大盤 |
| 03/16/2021 | 1134.57% | 羅斯資本 | $15→$20 | 維護 | 買 |
| 2020/08/17 | 702.47% | HC Wainwright公司 | →$13 | 升級 | 中性→購買 |
| 03/27/2020 | - | HC Wainwright公司 | 評級下調 | 購買→中性 | |
| 03/02/2020 | 393.83% | 奧本海默 | →$8 | 開始承保 | →跑贏大盤 |
| 2019年11月05日 | 393.83% | HC Wainwright公司 | →$8 | 開始承保 | →購買 |
What is the target price for aTyr Pharma (LIFE)?
ATyr Pharma(LIFE)的目標價是多少？
The latest price target for aTyr Pharma (NASDAQ: LIFE) was reported by HC Wainwright & Co. on September 21, 2023. The analyst firm set a price target for $35.00 expecting LIFE to rise to within 12 months (a possible 2060.49% upside). 13 analyst firms have reported ratings in the last year.
納斯達克(納斯達克代碼：LIFE)的最新目標價是由HC Wainwright&Co.於2023年9月21日報道的。這家分析公司將目標價格定為35美元，預計壽命將在12個月內上升(可能上漲2060.49%)。過去一年，有13家分析公司公佈了評級。
What is the most recent analyst rating for aTyr Pharma (LIFE)?
分析師對aTyr Pharma(LIFE)的最新評級是多少？
The latest analyst rating for aTyr Pharma (NASDAQ: LIFE) was provided by HC Wainwright & Co., and aTyr Pharma reiterated their buy rating.
分析師對aTyr Pharma(納斯達克代碼：LIFE)的最新評級由HC Wainwright&Co.提供，aTyr Pharma重申其買入評級。
When is the next analyst rating going to be posted or updated for aTyr Pharma (LIFE)?
ATyr Pharma(LIFE)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of aTyr Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for aTyr Pharma was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與aTyr Pharma的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。ATyr Pharma的上一次評級是在2023年9月21日提交的，所以你應該預計下一次評級將在2024年9月21日左右的某個時候提供。
Is the Analyst Rating aTyr Pharma (LIFE) correct?
分析師對aTyr Pharma(LIFE)的評級正確嗎？
While ratings are subjective and will change, the latest aTyr Pharma (LIFE) rating was a reiterated with a price target of $0.00 to $35.00. The current price aTyr Pharma (LIFE) is trading at is $1.62, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的aTyr Pharma(LIFE)評級被重申，目標價在0.00美元至35.00美元之間。目前aTyr Pharma(LIFE)的交易價格為1.62美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。